Davis Polk & Wardwell and Global Law Office are advising medical research firm CARsgen Therapeutics on its planned IPO in Hong Kong, with Herbert Smith Freehills and Zhong Lun Law Firm advising the joint underwriters. The IPO is expected to raise up to $400 million.

CARsgen is a biopharmaceutical company established in 2014, with operations in China and the U.S. It focuses on CAR-T cell therapies for the treatment of hematological malignancies and solid tumors.

Maples and Calder is providing the issuer offshore legal advice. The joint underwriters are Goldman Sachs and UBS.